The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation
Abstract
BACKGROUND: Nicotine is metabolized to cotinine, and cotinine is metabolized to 3'-hydroxycotinine (3-HC) by the liver enzyme cytochrome P450 (CYP) 2A6. More rapid metabolism of nicotine may result in lower nicotine blood levels from nicotine replacement products and poorer smoking cessation outcomes. This study evaluated the utility of the 3-HC/cotinine ratio as a predictor of the efficacy of nicotine replacement therapy as an aid for smoking cessation. METHODS: By use of an open-label design, 480 treatment-seeking smokers were randomly assigned to 8 weeks of transdermal nicotine or nicotine nasal spray use, plus behavioral group counseling. Assessments included demographics, smoking history, body mass index, and plasma nicotine, cotinine, and 3-HC concentrations, as well as CYP2A6 genotypes. Smoking cessation was biochemically verified at the end of treatment and at 6-month follow-up. RESULTS: The rate of nicotine metabolism, as indicated by pretreatment 3-HC/cotinine ratio derived from cigarette smoking, predicted the effectiveness of transdermal nicotine at both time points. The odds of abstinence were reduced by almost 30% with each increasing quartile of metabolite ratio (odds ratio, 0.72 [95% confidence interval, 0.57-0.90]; P=.005). Higher metabolite ratios also predicted lower nicotine concentrations (beta=-1.72, t(179)=-3.31, P<.001), as well as more severe cravings for cigarettes after 1 week of treatment (beta=0.32, t(190)=2.91, P=.004). The metabolite ratio did not predict cessation with use of nicotine nasal spray (odds ratio, 1.05 [95% confidence interval, 0.83-1.33]; P=.68). CONCLUSION: The nicotine metabolite ratio might be useful in screening smokers to determine likely success with a standard dose of transdermal nicotine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub4 · Cited by 2,464
Biochemical verification of tobacco use and cessation
Benowitz, N. L., III, P. J., Ahijevych, K., Jarvis, M. J., Hall, S., LeHouezec, J., Hansson, A., Lichtenstein, E., Henningfield, J., Tsoh, J., et al. (2002) · Nicotine & Tobacco Research · doi:10.1080/14622200210123581 · Cited by 1,800
Self-citationMeasures of abstinence in clinical trials: issues and recommendations
Hughes, J. R., Keely, J. P., Niaura, R. S., Ossip-Klein, D. J., Richmond, R. L., & Swan, G. E. (2003) · Nicotine & Tobacco Research · doi:10.1093/ntr/5.1.13 · Cited by 1,058
Metabolism of nicotine to cotinine studied by a dual stable isotope method
Benowitz, N. L., & Jacob, P. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.169 · Cited by 508
Self-citationReliability and validity of a smoking timeline follow-back interview.
Brown, R. A., Burgess, E. S., Sales, S. D., Whiteley, J. A., Evans, D. M., & Miller, I. W. (1998) · Psychology of Addictive Behaviors · doi:10.1037//0893-164x.12.2.101 · Cited by 489
A Major Role for CYP2A6 in Nicotine C-Oxidation by Human Liver Microsomes
Messina, E. S., Tyndale, R. F., & Sellers, E. M. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36947-2 · Cited by 453
Self-citationNicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity*1
DEMPSEY, D. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.02.011 · Cited by 429
Craving is associated with smoking relapse: Findings from three prospective studies.
Killen, J. D., & Fortmann, S. P. (1997) · Experimental and Clinical Psychopharmacology · doi:10.1037//1064-1297.5.2.137 · Cited by 419
Predicting Smoking Cessation: Who Will Quit With and Without the Nicotine Patch
Kenford, S. L. (1994) · JAMA · doi:10.1001/jama.271.8.589 · Cited by 405
Cited by
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub4 · Cited by 2,464
Benowitz, N. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0809890 · Cited by 1,508
Self-citationPharmacology of nicotine: addiction, smoking-induced disease, and therapeutics
Benowitz, N. L. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094742 · Cited by 979
“In one trial, comparing transdermal nicotine and nicotine nasal spray, the nicotine metabolite ratio was shown to be a strong predictor of smoking cessation both at the end of treatment and at six months in people treated with transdermal nicotine, but not with nicotine nasal spray (87).”
BackgroundSelf-citationNicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., & Lancaster, T. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub3 · Cited by 721
Benowitz, N. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.3 · Cited by 517
Self-citationInterventions for preventing weight gain after smoking cessation
Farley, A. C., Hajek, P., Lycett, D., & Aveyard, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006219.pub3 · Cited by 334
Lerman, C., Schnoll, R. A., Hawk, L. W., Cinciripini, P., George, T. P., Wileyto, E. P., Swan, G. E., Benowitz, N. L., Heitjan, D. F., & Tyndale, R. F. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70294-2 · Cited by 300
Self-citationScott, S. A., Sangkuhl, K., Shuldiner, A. R., Hulot, J.-S., Thorn, C. F., Altman, R. B., & Klein, T. E. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834d4962 · Cited by 261
Lindson, N., Chepkin, S. C., Ye, W., Fanshawe, T. R., Bullen, C., & Hartmann-Boyce, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013308 · Cited by 254
Association of COMT Val108/158Met genotype with smoking cessation
Munafò, M. R., Johnstone, E. C., Guo, B., Murphy, M. F. G., & Aveyard, P. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f44daa · Cited by 68
Sleep Disturbance During Smoking Cessation: Withdrawal or Side Effect of Treatment?
Ashare, R. L., Lerman, C., Tyndale, R. F., Hawk, L. W., George, T. P., Cinciripini, P., & Schnoll, R. A. (2017) · Journal of Smoking Cessation · doi:10.1017/jsc.2016.11 · Cited by 42
Self-citationRacial Differences in Attitudes toward Personalized Medicine
Diaz, V. A., Mainous III, A. G., Gavin, J. K., & Wilson, D. (2014) · Public Health Genomics · doi:10.1159/000354785 · Cited by 36
Vaz, L. R., Coleman, T., Cooper, S., Aveyard, P., & Leonardi-Bee, J. (2015) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntu342 · Cited by 27
Nicotine intake and smoking topography in smokers with bipolar disorder
Williams, J. M., Gandhi, K. K., Lu, S., Steinberg, M. L., & Benowitz, N. L. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2012.01047.x · Cited by 21
Self-citation
Metadata
- Authors
- LERMAN, C., TYNDALE, R., PATTERSON, F., WILEYTO, E., SHIELDS, P., PINTO, A., & BENOWITZ, N.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2006-06
- Volume
- 79
- Issue
- 6
- Pages
- 600-608
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2015234747
- Cited by
- 280
- References
- 28
- FWCI
- 10.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.